« Back
Home /
Setanaxib

Setanaxib

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neural Lineage Markers Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Clone	N/A
Amount	50 mg
Item no.	HY-12298-50mg
Targets	NADPH Oxidase; Ferroptosis
CASRN	1218942-37-0
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	394.85
Clinical_Information	Phase 2
Manufacturers Research_Area	Cardiovascular Disease
Solubility	DMSO : 125 mg/mL (ultrasonic)
Manufacturers Target	Ferroptosis; NADPH Oxidase
Isoform	NOX1; NOX4
Pathway	Apoptosis; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12298-50mg-safety-datasheet.pdf